31
Dietrich Wilhelm Schacht, Mike Hannay, Hans Michael Wolff: Transdermal delivery system for the administration of rotigotine. Nath & Associates, April 14, 2005: US20050079206-A1

An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid sem ...


32
Armin Breitenbach, Hans Michael Wolff: Hot melt tts for administering rotigotine. Schwarz Pharma, Edwards & Angell, November 24, 2005: US20050260254-A1

The invention relates to a transdermal therapeutic system (TTS) which contains a rotigotine-containing adhesive layer and is characterized by the fact that the adhesive layer contains a hot-meltable contact adhesive. The invention also relates to the use of rotigotine for producing the adhesive laye ...


33
Dietrich Wilhelm Schacht, Mike Hannay, Hans Michael Wolff: Transdermal delivery system. Nath & Associates Pllc, April 29, 2004: US20040081683-A1

An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a selfadhesive matrix containing an amine-functional drug and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or s ...


34
Frank Dressen, Dietrich Schacht, Hans Michael Wolff: Device for transdermal administration for the treatment of urinary tract disorders. Edwards & Angell, October 13, 2005: US20050226919-A1

This invention provides a device containing a compound of formula (I), wherein R represents a saturated or unsaturated C2-7 aliphatic acyl group optionally substituted by one or more halogen atoms, a hydroxy group, a C1-6 alkoxy group, a carboxyl group, a C2-7 alkoxycarbonyl group, a 5 to 7-membered ...


35
Armin Breitenbach, Claus Meese, Hans Michael Wolff, Roland Drews: Highly pure bases of 3,3-dipheyl propylamine monoesters. Schwarz Pharma, Kenyon & Kenyon, January 19, 2006: US20060014832-A1

The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deu ...


36
Armin Breitenbach, Claus Meese, Hans Michael Wolff, Roland Drews: Transdermal administration of (r)-3,3-diphenylpropylamin-monoesters. Schwarz Pharma, Edwards & Angell, February 9, 2006: US20060029673-A1

The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, ni ...


37
Hans Michael Wolff: Transdermal therapeutic system for Parkinsons Disease. Jones Day, September 28, 2006: US20060216336-A1

The invention provides a transdermal therapeutic system (TTS) containing rotigotine as the active ingredient. The TTS is useful in the treatment of Parkinson's Disease because it induces a pharmacokinetic profile where the rotigotine plasma level is high and stable.


38
Armin Breitenbach, Claus Meese, Hans Michael Wolff, Roland Drews: High purity bases of 3,3-diphenylpropylamino monoesters. Kenyon & Kenyon, January 8, 2009: US20090012159-A1

The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deu ...


39
Dietrich Wilhelm Schacht, Mike Hannay, Hans Michael Wolff: Transdermal delivery system for the administration of rotigotine. UCB Pharma, August 23, 2012: US20120215185-A1

An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use,characterized in that the self-adhesive matrix consists of a solid or semi-solid semi ...


40
Hans Michael Wolff, Luc Quere, Jens Riedner: Novel polymorphic form of rotigotine and process for production. Ucb Pharma, Harness Dickey & Pierce, December 9, 2010: US20100311806-A1

The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X-ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01±0.2 (°2θ), measured with a Cu—Kαirradiation (1.54060), and a process for production thereof, which is useful for the ma ...